XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.34

-2.1%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (17262)	1/11/2007 1:06:16 AM
From: bob zagorin	of 17367

from the most recent zacks report "...Royalty revenue continues to provide meaningful growth to Xoma. Raptiva sales outside the U.S. remain strong. Lucentis royalty should really help accelerate the overall royalty line in the next several quarters. U.S. sales of Lucentis at Genentech blew away expectations in the third quarter of 2006. We expect another royalty product, UCB s Cimzia, to gain approval early 2007, bringing the total royalty product suite to three...."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next